# Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct02665065/  
OnCo record `nct02665065` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Iomab-B run by Actinium Pharmaceuticals, active.

## Summary

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT02665065 by Actinium Pharmaceuticals, with 153 participants enrolled, started 2016-06. Conditions listed: Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02665065
- Phase: 3
- Setting: A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Sponsor: Actinium Pharmaceuticals
- Enrolled: 153

## Sources

- ClinicalTrials.gov NCT02665065: https://clinicaltrials.gov/study/NCT02665065

## Connected records

- drugs: [Iomab-B](https://onco.cc/drugs/iomab-b/)
- companies: [Actinium Pharmaceuticals](https://onco.cc/companies/actinium-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct02665065.json